ADORA2A and Alzheimer disease: Similar to α1-AR, treatment with α2-AR antagonists including fluparoxan (Scullion et al., 2011), dexefaroxan (Francis et al., 2012), and mesedin (Melkonyan et al., 2017) was found to be beneficial for improving AD-like pathological mechanisms (Table 2).